Business news and discussion on TalkFuse.
Celebrity-backed cancer treatment venture eyes London listing
Ellipses Pharma, a clinical-stage cancer drug venture founded by British biotech entrepreneur Sir Chris Evans, is preparing to list in London through a reverse takeover. The proposed deal could value the company at £450m to £500m and would be a boost for a London market facing a decline in new listings, including in biotech and pharmaceuticals.
The company’s investors include Evans, Jimmy Carr, Andrew Lloyd Webber, Steve Morgan and Sir Tom Hunter’s West Coast Capital; Abu Dhabi’s Mubadala sovereign wealth fund is its largest investor, with a 45 per cent stake. Ellipses employs around 40 people and has invested about £185m in its drug pipeline. It is targeting a listing as soon as February by merging with cash shell Wolfram Resources, with advisers reportedly appointed and a formal announcement possible this week.
In short
- Ellipses Pharma is targeting a London listing through a reverse takeover.
- The deal could value the cancer drug venture at £450m to £500m.
- Abu Dhabi’s Mubadala fund holds a 45 per cent stake.
Business Celebrity Companies Entertainment Health Markets Medicine UK World